Completed PHASE2 INTERVENTIONAL 1-arm NCT00237458

An Open-label Continuation Trial to Assess the Continued Efficacy and Safety of Ascending Doses of Lacosamide in Subjects With Chronic Refractory Neuropathic Pain

Sponsor: UCB Pharma

Conditions Chronic Refractory Neuropathic Pain

Interventions Lacosamide

Updated 6 times since 2017 Last updated: Jul 28, 2017 Started: May 31, 2001 Primary completion: Mar 31, 2011 Completion: Mar 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00237458, this PHASE2 trial focuses on Chronic Refractory Neuropathic Pain and remains completed. Sponsored by UCB Pharma, it has been updated 6 times since 2001, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

May 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

UCB Pharma

Data source: UCB Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Monheim, Germany